227. Osler disease Clinical trials / Disease details

Clinical trials : 56 / Drugs : 72 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03910244 (ClinicalTrials.gov)	October 17, 2019	8/4/2019	Pomalidomide for the Treatment of Bleeding in HHT	Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia	Telangiectasia, Hereditary Hemorrhagic	Drug: Pomalidomide Oral Product;Drug: Placebo oral capsule	The Cleveland Clinic	RTI International	Recruiting	18 Years	N/A	All	159	Phase 2	United States
2	NCT02287558 (ClinicalTrials.gov)	January 27, 2015	6/11/2014	Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study	A Phase I Single Arm Study to Assess the Safety and Efficacy of Pomalidomide in Patients With Bleeding Due to Hereditary Hemorrhagic Telangiectasia and Refractory Angiodysplasia	Hereditary Hemorrhagic Telangiectasia;Idiopathic Vascular Ectasia	Drug: Pomalidomide	The Cleveland Clinic	NULL	Completed	18 Years	N/A	All	9	Phase 1	United States